Buying guide
Lingo vs Samsung Galaxy Watch (and Galaxy Ring) in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Abbott | Samsung Electronics |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $300 (actual sale price) |
| Capability claims | — | — |
| Brain | — | — |
| Verified deployments | 1Abbott | 1Samsung Electronics |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 10cloud-upload, third-party-sharing, data-sale, data-retention, on-device-processing, location-tracking, biometric-storage, data-sale, data-deletion-control, data-retention |
| Sources on file | 8 | 13 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Samsung Galaxy Watch (and Galaxy Ring)
The Samsung Galaxy Watch (the Galaxy Watch 7 anchor at about $300, plus the Watch Ultra and the adjacent Galaxy Ring, all July 2024) is a biometric-primary smartwatch whose BioActive sensor combines optical heart rate, electrical ECG, and bioimpedance. Its FDA-cleared features (held by the Samsung Health Monitor app) include ECG (2021), AFib detection (2023), and sleep-apnea detection (De Novo, February 2024), with no subscription. A within-entity verified-vs-claimed exemplar: Samsung's blood-pressure feature is cleared in Korea and several other markets but NOT in the US, where it remains wellness-grade; DEPLOY surfaces that market-specific clearance variance honestly rather than implying a US clearance. The Galaxy Ring is an adjacent biometric form factor (accelerometer, optical HR, skin temperature for sleep, heart rate, and an Energy Score) with no ECG and no FDA-cleared features.
Machine-readable: this page as markdown.